Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years

Cancer

Volumn 103, Issue 4, 2005, Pages 708-716

  Postma, Rensbe ^a,b   De Vries, Shijn H ^a   Roobol, Monique J ^a   Wildhagen, Mark F ^a   Schröder, Fritz H ^a   Van Der Kwast, Theo H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Focal carcinoma; Prostate carcinoma; Radical prostatectomy; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SCREENING; CLINICAL FEATURE; DISEASE COURSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

AGED; BIOPSY, NEEDLE; DISEASE PROGRESSION; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 13444268954     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20840     Document Type: Article

References (28)

1. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998;148:775-785.
2. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868-878.
3. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71(3 Suppl):933-938.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non-palpable (Stage T1c) prostate cancer. JAMA. 1994;271:368-374.
5. Stamey TA. More information on prostate specific antigen and prostate cancer. J Urol. 2003;170(2 Pt 1):457-458.
6. Stephenson AJ, Aprikian AG, Souhami L, et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology. 2002;59:652-656.
7. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer. 1998;82:342-348.
8. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol. 2000;163:806-812.
9. Schroder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 1998;90:1817-1823.
10. Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int. 2003;92(Suppl 2):48-54.
11. Hoedemaeker RRE, Ruizeveld de Winter JA, Van der Kaa CA, van der Kwast TH. Processing radical prostatectomy specimens, a comprehensive and standardized protocol. J Urol Pathol 1998;9:211-222.
12. Hoedemaeker RF, van der Kwast TH, Schröder FH. The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy. BJU Int. 2003;92(Suppl 2):92-96.
13. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803-1804.
14. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843-848.
15. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
16. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62:866-871.
17. Yurdakul G, Bangma CH, Blijenberg BG, et al. Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol. 2002;42:154-158.
18. Reid BC, Alberg AJ, Klassen AC, Koch WM, Samet JM. The American Society of Anesthesiologists' class as a comorbidity index in a cohort of head and neck cancer surgical patients. Head Neck. 2001;23:985-994.
19. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 2001:166:104-109; discussion, 109-110.
20. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol. 1995;153: 1543-1548.
21. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol. 2003;170(2 Pt 1): 370-372.
22. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤ 7. Cancer. 2000;89:1810-1817.
23. Hoedemaeker RF, van der Kwast TH, Boer R, et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst. 2001; 93:1153-1158.
24. Herkommer K, Kuefer R, Gschwend JE, Hautmann RE, Volkmer BG. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol. 2004;45:36-41.
25. Choo R, DeBoer G, Klotz L, et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001;50:615-620.
26. Raaijmakers R, Wildhagen MF, Ito K, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology. 2004;63:316-320.
27. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002;167:1231-1234.
28. Postma R, Roobol M, Schroder FH, van der Kwast TH. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer. 2004; 100:968-975.